ViGeneron

News

Germany’s ViGeneron is to advance development of its next-generation ophthalmology gene therapy pipeline after a series A financing round.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.